Trials / Completed
CompletedNCT05683496
Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
A Phase 1/2, Adaptive, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of Lonigutamab in Subjects With Thyroid Eye Disease (TED)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- ACELYRIN Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lonigutamab | subcutaneous injection |
| DRUG | Placebo | subcutaneous injection |
Timeline
- Start date
- 2023-02-14
- Primary completion
- 2025-05-26
- Completion
- 2025-05-26
- First posted
- 2023-01-13
- Last updated
- 2025-07-01
Locations
11 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05683496. Inclusion in this directory is not an endorsement.